CDRH’s Shuren Says Employee Burnout ‘Great Fear’ During Pandemic
Executive Summary
The US FDA’s device center has reassigned staff and let some product reviews fall to the back burner while it grapples with a crush of new product applications tied to COVID-19.
You may also be interested in...
Woodcock: Use Of Real-World Evidence Still Brings ‘A Lot Of Problems’
US FDA acting commissioner Janet Woodcock says the use of real-world evidence in product reviews will be slower than many of its supporters are hoping because there are a number of problems that still need to be addressed.
COVID-19 And FDA: Official Tells How Pandemic Has Affected Agency’s Regulatory Work
US FDA device center associate director Erin Keith explained how the agency adapted – and continues to adapt – to the COVID-19 pandemic when it comes to medical device and diagnostic regulation.
US FDA Recognizes Case For Quality Collaborative Community
The Case for Quality Collaborative Community – or CfQcc – affords stakeholders across industry a safe space where they can rally around an array of topics to advance medical device quality and safety.